Episode

Can We Make a Drug for One Person?

Podcast
Galaxy Balance
Published
Aug 24, 2026
Duration seconds
3820
Processing state
not_requested
Canonical source
https://api.riverside.com/hosting-analytics/media/ccc319887a8217a541d9be5a5d30dafeb774cbe759d2e0a34e11f482fd0daa98/eyJlcGlzb2RlSWQiOiI4MTE1NWFhYi00ZGFlLTQ5MDktODhkNS0yODdhYmJkNTNmNzEiLCJwb2RjYXN0SWQiOiJjMGE0YjQ3Yi1iMmM5LTRjNjgtODhiNS0xYmFhM2EzNTJjODMiLCJhY2NvdW50SWQiOiI2OTBiYjRiMzM2NjY3MWFlZGQwZTZhMTEiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmE4YzI5NTFmMjY5Y2ZkMTVmNTYwY2Y1L2Nvcnktc21pdGhzLXN0dWRpby1sTktuWC1jb21wb3Nlci0yMDI2LTgtMjRfXzEzLTIxLTUyLm1wMyJ9.mp3
Audio
https://api.riverside.com/hosting-analytics/media/ccc319887a8217a541d9be5a5d30dafeb774cbe759d2e0a34e11f482fd0daa98/eyJlcGlzb2RlSWQiOiI4MTE1NWFhYi00ZGFlLTQ5MDktODhkNS0yODdhYmJkNTNmNzEiLCJwb2RjYXN0SWQiOiJjMGE0YjQ3Yi1iMmM5LTRjNjgtODhiNS0xYmFhM2EzNTJjODMiLCJhY2NvdW50SWQiOiI2OTBiYjRiMzM2NjY3MWFlZGQwZTZhMTEiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmE4YzI5NTFmMjY5Y2ZkMTVmNTYwY2Y1L2Nvcnktc21pdGhzLXN0dWRpby1sTktuWC1jb21wb3Nlci0yMDI2LTgtMjRfXzEzLTIxLTUyLm1wMyJ9.mp3
JSON
/v1/public/podcasts/galaxy-balance-7619530/episodes/can-we-make-a-drug-for-one-person
Markdown
/podcast/galaxy-balance-7619530/can-we-make-a-drug-for-one-person.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/galaxy-balance-7619530/episodes/can-we-make-a-drug-for-one-person/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/galaxy-balance-7619530/can-we-make-a-drug-for-one-person.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

What if we could design a medicine for a single person? Casey McPherson was a musician and songwriter when his daughter Rose was diagnosed with an ultra-rare neurogenetic disease. There was no approved treatment and no clear path forward. Rather than accepting that answer, Casey began learning genetics, building a network of scientists, and ultimately creating the infrastructure needed to develop a treatment for his daughter. Today, Casey is the CEO and co-founder of Alpha Rose Therapeutics, where his team is working to make individualized genetic medicine scalable. Their approach combines antisense oligonucleotides, patient-derived stem cells, AI-guided therapeutic design, automation, and a new economic model for diseases that traditional drug development often leaves behind. We discuss how Alpha Rose reduced a therapeutic amenability analysis that once took months to just minutes using AI, why Casey believes drug development should eventually be approved as a repeatable process rather than one drug at a time, and how point-of-care synthesis could allow personalized genetic medicines to be produced rapidly for individual patients. We also explore autonomous laboratories, AI scientists, patient-derived iPSCs and brain organoids, the economics of rare disease, genetic enhancement, and a future of medicine that looks increasingly like the sick bay of Star Trek: understand the unique biology of the patient, design the intervention, synthesize it, and treat them. Casey's story raises a much bigger question. Are rare diseases really rare, or are they the first glimpse of a future where every disease becomes individualized? 00:00 - Casey McPherson’s path from musician to biotech founder 01:38 - Childhood curiosity: music, programming, electronics, and biology 04:16 - Rose’s…